Donald Milligan

Medicine · Health Sciences

48h-index10.2kcitations124works31.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Acute Myeloid Leukemia Research(45), Chronic Lymphocytic Leukemia Research(37), Acute Lymphoblastic Leukemia research(29), Lymphoma Diagnosis and Treatment(27), Chronic Myeloid Leukemia Treatments(27)

Publications124 total

Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With <i>NPM1</i> and <i>FLT3</i> Mutations
Journal of Clinical Oncology·2024· 31 citedOpen Access
Eradication of minimal residual disease improves overall and progression‐free survival in patients with chronic lymphocytic leukaemia, evidence from <scp>NCRN CLL</scp>207: a phase <scp>II</scp> trial assessing alemtuzumab consolidation
British Journal of Haematology·2016· 17 cited
An operational definition of primary refractory acute myeloid leukemia allowing early identification of patients who may benefit from allogeneic stem cell transplantation
Haematologica·2016· 92 citedOpen Access
An Operational Definition of Primary Refractory Acute Myeloid Leukaemia Which Allows Early Identification of Patients for Whom Allogeneic Stem Cell Transplantation Represents the Only Curative Therapy
Blood·2015· 3 cited
Quadruplet Vs Sequential Triplet Induction Therapy Approaches to Maximise Response for Newly Diagnosed, Transplant Eligible, Myeloma Patients
Blood·2015· 4 cited
Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis
JAMA Oncology·2015· 454 cited
Final results of EFC6663: A multicenter, international, phase 2 study of alvocidib for patients with fludarabine-refractory chronic lymphocytic leukemia
Leukemia Research·2015· 50 citedOpen Access
A Comparison of Single Dose Gemtuzumab Ozogamicin 3mg/m2 and 6mg/m2 Combined with Induction Chemotherapy in Younger Patients with AML: Data from the UK NCRI AML17 Trial
Blood·2014· 3 cited
A Randomised Comparison of Daunorubicin 90mg/m2 Vs 60mg/m2 in AML Induction: Results from the UK NCRI AML17 Trial in 1206 Patients
Blood·2014· 4 cited
A Randomised Assessment of Vosaroxin Monotherapy and Vosaroxin Combined with Low Dose Ara-C Versus Low Dose Ara-C in Older Patients with Acute Myeloid Leukaemia
Blood·2014
A Randomised Comparison of the Sequential Addition of the FLT3 Inhibitor Lestaurtinib (CEP701) to Standard First Line Chemotherapy for FLT3-Mutated Acute Myeloid Leukemia: The UK Experience
Blood·2014· 7 cited
Optimizing induction and pretransplant consolidation for myeloma: Results of Myeloma XI, a phase III trial comparing different IMiDs.
Journal of Clinical Oncology·2014
Rituximab Plus Chlorambucil As First-Line Treatment for Chronic Lymphocytic Leukemia: Final Analysis of an Open-Label Phase II Study
Journal of Clinical Oncology·2014· 121 citedOpen Access
Pre-Transplantation Assessment Of Mortality (PAM) Score Is a Poor Predictor For Survival In The Highest Risk Group When Used In T Cell Depleted Myeloablative Allogeneic Transplants
Blood·2013· 2 cited
Lenalidomide Combined With Cyclophosphamide and Dexamethasone Is Effective and Well Tolerated Induction Treatment For Newly Diagnosed Myeloma Patients Of All Ages
Blood·2013· 6 cited
Newly Diagnosed Multiple Myeloma (MM) Patients Treated With Lenalidomide Induction and Maintenance Show a Low Incidence Of Second Primary Malignancies (SPMs)
Blood·2013· 2 cited
AC220 (Quizartinib) Can Be Safely Combined With Conventional Chemotherapy In Older Patients With Newly Diagnosed Acute Myeloid Leukaemia: Experience From The AML18 Pilot Trial
Blood·2013· 41 cited
Results Of The Randomised Phase II NCRI Arctic (Attenuated dose Rituximab with ChemoTherapy In CLL) Trial Of Low Dose Rituximab In Previously Untreated CLL
Blood·2013· 4 cited
Reasons For Survival Improvement In Core Binding Factor AML: A 25 Year Analysis Of The UK MRC/NCRI AML Trials
Blood·2013· 12 cited
The ATRA Question In AML: Lack Of Benefit Overall Or In Any Molecular Subgroup In The NCRI AML16 Trial
Blood·2013· 5 cited
page 1 of 7Next →

Frequent Co-authors

Anthony H. Goldstone(17), Stephen Mackinnon(15), Keith Wheatley(14), Chris Fegan(14), Robert K. Hills(13), Alan K. Burnett(12), Nigel H. Russell(12), David C. Linch(11), Karl S. Peggs(10), G Hale(10), Charles Craddock(10), Ann Hunter(9), Suparno Chakrabarti(9), Panagiotis Kottaridis(8), Premini Mahendra(8), Herman Waldmann(8), Anne Parker(7), Rajesh Chopra(6), Kirsty Thomson(6), Ronjon Chakraverty(5)